Recent developments include a break-even earnings report for Q4 2025, updates on clinical and commercialization programs, and a capital raise through a $15 million upsized offering.

• Plus Therapeutics reported break-even earnings for Q4 2025 [N1].
• The company set 2026 milestones for the REYOBIQ clinical program and CNSide commercial rollout [N5].
• Plus Therapeutics provided a business update on the REYOBIQ clinical program and U.S. CNSide commercialization in January 2026 [N6].
• The company advanced its radiotherapeutic pipeline and provided a business update in January 2026 [N7].
• In January 2026, Plus Therapeutics completed a $15 million upsized offering [N8].

The company has demonstrated progress in clinical development and commercialization efforts, including setting 2026 milestones for its REYOBIQ clinical program and CNSide commercial rollout. Its proprietary nanomedicine candidates and diagnostic tests address unmet needs in cancer treatment and detection. Recent capital raises provide liquidity to support ongoing operations and development. Continued advancement in clinical programs and successful commercialization could enhance its market position.

Plus Therapeutics operates in a highly competitive and rapidly evolving industry with significant risks related to technological obsolescence, intellectual property challenges, and regulatory hurdles. The company has reported substantial net losses and relies on capital raises to fund operations, which may dilute existing shareholders. Risks include potential patent litigation, failure to obtain or maintain patent protection, and the possibility that clinical programs may not yield favorable outcomes or regulatory approvals.

Plus Therapeutics' moat is primarily based on its proprietary nanomedicine technologies and the CNSide diagnostic platform, supported by patent protections and trade secrets. The company faces challenges in maintaining and defending its intellectual property rights amid complex and evolving patent landscapes. Its ability to innovate and protect its technology, alongside regulatory approvals, underpins its competitive position in the oncology treatment and diagnostic markets.

• Intellectual Property Risks: The company faces risks related to patent validity, third-party challenges, potential infringement claims, and the ability to protect trade secrets. Litigation and patent disputes could result in substantial costs and operational disruptions [S1].
• Technological Obsolescence: Rapid changes in diagnostic and treatment technologies require continuous product updates. Failure to keep pace with scientific advances could render products obsolete and negatively impact sales [S1].
• Financial and Capital Risks: The company has reported net losses and depends on capital raises to fund operations. Issuance of additional shares may dilute existing shareholders. Liquidity ratios indicate moderate short-term financial health [S1].
• Regulatory and Compliance Risks: Compliance with healthcare laws and regulations is complex and costly. Non-compliance could result in penalties, reputational harm, and operational restrictions [S1].
• Cybersecurity Risks: Despite implemented cybersecurity measures, evolving threats could compromise data and operations, potentially affecting reputation and results [S1].

• Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing, manufacturing, and commercializing complex and innovative treatments for cancer and other life-threatening diseases [S2].
• The company has a wholly owned subsidiary, CNSide Diagnostics, LLC, which develops and commercializes proprietary laboratory-developed tests, including the CNSide Test for detecting tumor cells metastasized to the central nervous system in carcinoma and melanoma patients [S2].
• Plus Therapeutics' product candidates include nanomedicine candidates such as rhenium (186 Re) obisbemeda and 188 RNL-BAM, and the CNSide Platform [S1].
• The company faces risks related to rapid technological changes in the diagnostic testing industry, which could render current or future products obsolete if not updated to reflect new scientific knowledge and standards of care [S1].
• Intellectual property protection is critical to the company's success, with risks including patent validity, third-party challenges, and potential infringement claims [S1].
• The company has implemented a cybersecurity program with safeguards such as password protection, multi-factor authentication, and monitoring systems; no material cybersecurity incidents have been reported [S1].
• Financial figures as of December 31, 2025, include cash and cash equivalents of $4.256 million, short-term investments of $4.356 million, current assets of $15.17 million, and current liabilities of $12.314 million, resulting in a current ratio of 1.23 and a cash ratio of 0.7 [S1].
• For the fiscal year ended December 31, 2025, Plus Therapeutics reported revenue of $5.213 million and a net loss of $22.386 million, with basic and diluted EPS of -$0.29 [S1].
• Recent quarterly results include a break-even earnings report for Q4 2025 [N1].
• The company has set 2026 milestones for the REYOBIQ clinical program and CNSide commercial rollout [N5].
• Plus Therapeutics provided a business update on the REYOBIQ clinical program and U.S. CNSide commercialization in January 2026 [N6].
• The company advanced its radiotherapeutic pipeline and provided a business update in January 2026 [N7].
• In January 2026, Plus Therapeutics completed a $15 million upsized offering [N8].